{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:59:09Z","timestamp":1791874749799,"version":"4.3.4"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background and Objective: Zanubrutinib, a next-generation Bruton\u2019s tyrosine kinase inhibitor (BTKi), has demonstrated promising efficacy in chronic lymphocytic leukemia (CLL), including treatment-na\u00efve (TN) and relapsed\/refractory (R\/R) patients. However, evidence synthesis across clinical trials remains limited. We conducted a systematic review and single-arm meta-analysis to evaluate the efficacy of zanubrutinib in CLL. Methods: This study was performed in accordance with PRISMA guidelines and Cochrane recommendations. PubMed, Medline, Scopus, and Web of Science were searched up to August 2025 using terms related to zanubrutinib and CLL\/SLL. Eligible studies included clinical trials of zanubrutinib in TN or R\/R CLL\/SLL patients. Risk of bias was assessed using the JBI tool for non-randomized studies and for RCTs. Pooled estimates of efficacy outcomes were calculated using a random-effects model. Pooled estimates were calculated using the DerSimonian\u2013Laird random-effects model, which accounts for both within- and between-study variability. Results: Seven studies (n &gt; 1000) were included, enrolling both TN and R\/R patients across diverse global populations. The pooled overall response rate (ORR) was 93.3% (95% CI, 86.7\u201399.8%) in mixed TN and R\/R populations, 94.4% (95% CI, 91.6\u201397.3%) in TN patients, and 83.9% (95% CI, 75.0\u201392.8%) in R\/R patients. Complete response (CR) rates were 12.2% (95% CI, 0.3\u201324.2%) overall, 13.8% (95% CI, 1.5\u201326.2%) in TN patients, and 5.0% (95% CI, 0.3\u20139.8%) in R\/R patients. Partial response (PR) rates reached 86.0% (95% CI, 82.6\u201389.5%) in TN and 63.2% (95% CI, 53.5\u201373.0%) in R\/R patients. Progressive disease was rare (\u22641% in R\/R cohorts). Heterogeneity was moderate to high across several outcomes. Conclusions: Zanubrutinib demonstrates favorable efficacy in CLL, achieving high ORR in both TN and R\/R patients, with particularly durable responses in TN populations. Although complete response rates remain modest, especially among R\/R patients, overall disease control appears consistent. These findings support zanubrutinib as an effective treatment option across CLL settings; however, variability among studies and the modest CR rates highlight the need for longer follow-up and direct comparative trials to further define its clinical role.<\/jats:p>","DOI":"10.3390\/ph18111674","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:19:29Z","timestamp":1762348769000},"page":"1674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8167-6931","authenticated-orcid":false,"given":"Yasser","family":"Alatawi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz E.","family":"Alanazi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-7723","authenticated-orcid":false,"given":"Abdullah","family":"Alattar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0576-9188","authenticated-orcid":false,"given":"Reem","family":"Alshaman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7374-9334","authenticated-orcid":false,"given":"Yasmin N.","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Assiut University, Assiut 71515, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-2714","authenticated-orcid":false,"given":"Reem","family":"Sayad","sequence":"additional","affiliation":[{"name":"Department of Histology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-8246","authenticated-orcid":false,"given":"Helal F.","family":"Hetta","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"840616","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study","volume":"12","author":"Ou","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_2","first-page":"493","article-title":"Chronic lymphocytic leukaemia: An updated approach to diagnosis and management in general practice","volume":"46","author":"Tomlinson","year":"2017","journal-title":"Aust. Fam. Physician"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/hematology.2020000086","article-title":"Standard treatment approaches for relapsed\/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy","volume":"2020","author":"Moreno","year":"2020","journal-title":"Hematol.-Am. Soc. Hematol. Educ. Program"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40272-022-00543-w","article-title":"Ibrutinib: Pediatric first approval","volume":"25","author":"Keam","year":"2023","journal-title":"Pediatr. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jha2.619","article-title":"Zanubrutinib in patients with treatment-na\u00efve or relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: An expanded-access study of 50 patients in the United States","volume":"4","author":"Castillo","year":"2023","journal-title":"EJHaem"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2022). Zanubrutinib (Brukinsa). Can. J. Health Technol., 2, 123.","DOI":"10.51731\/cjht.2022.453"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-025-03925-1","article-title":"Zanubrutinib in Japanese treatment-naive and relapsed\/refractory patients with Waldenstrom macroglobulinemia and CLL\/SLL","volume":"121","author":"Izutsu","year":"2025","journal-title":"Int. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Higgins, J. (2008). Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Collaboration John Wiley Sons Ltd.","DOI":"10.1002\/9780470712184"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"key":"ref_17","first-page":"2127","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/bloodadvances.2024015493","article-title":"Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: Updated results","volume":"9","author":"Shadman","year":"2025","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.27519","article-title":"Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia\/small lymphocytic lymphoma: A multicenter, real-world study in China","volume":"100","author":"Luo","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/bjh.17994","article-title":"Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: Long-term follow-up of the phase I\/II AU-003 study","volume":"196","author":"Cull","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_23","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: Final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:33:23Z","timestamp":1762349603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ph18111674"],"URL":"https:\/\/doi.org\/10.3390\/ph18111674","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}